Managing the drug treatment of rheumatoid arthritis

Affiliations

¹ School of Medicine, Nursing and Health Sciences, Flinders University, Adelaide.
² School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide.

Review

Tom D Wilsdon et al. Aust Prescr. 2017 Apr.

. 2017 Apr;40(2):51-58.

doi: 10.18773/austprescr.2017.012. Epub 2017 Apr 3.

¹ School of Medicine, Nursing and Health Sciences, Flinders University, Adelaide.
² School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide.

No abstract available

Keywords: disease-modifying antirheumatic drugs (DMARDs); immunosuppression; rheumatoid arthritis.

References

1. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014;73:1316-22. 10.1136/annrheumdis-2013-204627 - DOI - PubMed
1. Australian Institute of Health and Welfare. Rheumatoid arthritis. Canberra: AIHW; 2016. www.aihw.gov.au/rheumatoid-arthritis [cited 2017 Mar 1]
1. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74. 10.1016/S0140-6736(07)60784-3 - DOI - PubMed
1. Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65:1608-12. 10.1136/ard.2005.050377 - DOI - PMC - PubMed
1. Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010;49:295-307. 10.1093/rheumatology/kep366 - DOI - PubMed